Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 1.00 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.65 |
| ▸ | IGF2R | P11717 | 4/20 | 0.60 |
| ▸ | UMPS | P11172 | 4/20 | 0.47 |
| ▸ | ATIC | P31939 | 1/20 | 0.46 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30189347 | 1.00 | FBP1 (1.00) | FBP1AMDHD2IGF2RUMPSATIC | |
| SCHEMBL5436034 | 0.90 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSATIC | |
| SCHEMBL30471819 | 0.90 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSATIC | |
| SCHEMBL4997000 | 0.90 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSATIC | |
| SCHEMBL5001024 | 0.90 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSATIC | |
| SCHEMBL24450790 | 0.90 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSATIC | |
| SCHEMBL187934 | 0.90 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSATIC | |
| SCHEMBL4308485 | 0.90 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSATIC | |
| SCHEMBL708955 | 0.90 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSATIC | |
| SCHEMBL16710620 | 0.90 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSATIC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220142948-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-05-12 | — | — | US | claimed |
| EP-3942023-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | The Broad Institute, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| WO-2020191079-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | THE BROAD INSTITUTE, INC. (US) | 2020-09-24 | — | — | WO | claimed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220142948-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-05-12 | — | — | US | disclosed |
| EP-3942023-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | The Broad Institute, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020191079-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | THE BROAD INSTITUTE, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-10441564-B2 | Fructose analogs and their combinations as anti-cancer agents | Jia, Wei (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20180133192-A1 | Fructose analogs and their combinations as anti-cancer agents | JIA, WEI | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133192-A1 | Fructose analogs and their combinations as anti-cancer agents | ALDOA, FBP1, MPI | FBP1 2/4885AMDHD2 453/4885IGF2R 40/4885 |
| US-10441564-B2 | Fructose analogs and their combinations as anti-cancer agents | ALDOA, FBP1, MPI | FBP1 2/4885AMDHD2 443/4885IGF2R 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.